GlassScriptPhysician profile
Rachel Straus
NPI 1326621095
$1,918.89
in general payments reported to CMS, 2019-2025
14 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.12 · 2023: $246 · 2024: $378 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.77 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $517.52 | 2024-2025 | Opzelura, Opzelura |
| Abbvie INC. | $396.61 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $255.71 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $217.00 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $190.37 | 2022-2025 | |
| Janssen Biotech, INC. | $72.00 | 2025 | Tremfya |
| Genzyme Corporation | $57.74 | 2023-2025 | |
| Botanix Sb INC | $44.89 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $38.38 | 2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $33.89 | 2025 | |
| Ucb, INC. | $33.69 | 2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $28.44 | 2025 | Valchlor |
| Lilly USA, LLC | $23.86 | 2025 | Ebglyss |
| Biofrontera INC. | $8.79 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Straus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.